comprehensive -WSS

comprehensive

author：fashion 2025-09-07 06:42:25 - browse：63949

U.S. Sen. Bernie Sanders sets his hands on two chairs as two people set up a board displaying a "price of drugs" chart behind him — politics coverage from STAT — Sen. Bernie Sanders has used his leadership of a Senate committee to pressure drugmakers to lower their prices. Kevin Dietsch/Getty Images

WASHINGTON — Bernie Sanders is figuring out just how far bullying drugmakers can take him.

For more than a year, Sanders has used his perch atop the Senate health committee to haul the CEOs of pharmaceutical companies that make insulin, vaccines, and more before the panel with progressively more ambitious demands related to their pricing. After a few victories he’s claimed — experts say some credit is deserved, but the full story is a bit more complicated — he’s now progressed to demanding that Novo Nordisk cut its price for its novel, wildly popular diabetes and weight-loss drugs.

Sanders (I-Vt.) is testing the limits of the powers of a Senate chairman with little hope of advancing his policy agenda legislatively. He’s threatened subpoenas, held a prominent nominee hostage, and initiated investigations to get his way. It’s a sharp departure from the modest, bipartisan ambitions that more disciplined, discreet leaders of the committee have taken in years past, and sets the bar for how much can be accomplished using the full extent of the bully pulpit.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： High breast density mammograms need follow

hotspot

WSS

Prior authorization reform is both possible and imperative

Juul spent big to court Black leaders to promote its e

The real point of Kenneth Smith’s execution by nitrogen gas

A $475,000 price tag for a new cancer drug: crazy or meh?

Medicare drug price negotiation’s day in court

Medicare drug price negotiation’s day in court

hotspot

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

hotspot

Medicare proposal to cover medical devices draws a mixed reaction

High breast density mammograms need follow

George Santos makes 1st court appearance after pleading not guilty to 13 counts

FDA endorses new sterilization method for medical devices

Affirmative action in medical school literally saved lives

The lessons of Aduhelm, an Alzheimer's drug that was not to be

Novavax promises a turnaround & Lilly roils the obesity market

Biden administration opens offers in Medicare drug price negotiations

State Dept. review finds Biden bears some blame for Afghanistan failures

Juul spent big to court Black leaders to promote its e

focus

A $475,000 price tag for a new cancer drug: crazy or meh?

Cardiologists urge adding sexual orientation, gender identity to health records

Quicker fix for pulse oximeters urged during FDA public meeting

Do digital therapeutics have a future in medicine?

Immunocompromised patients offer clues on chronic Covid

There's an unseen cost to disruptive road

hotspot

focus

knowledge

entertainment